Sugi Predict

Sugi Predict / Compounds / SCHEMBL2460057

SCHEMBL2460057

SCHEMBL2460057

N[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2cccc(OC(F)(F)F)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.35
▸ MRGPRX4 Q96LA9 3/20 0.34
▸ CYP19A1 P11511 2/20 0.33
▸ CYP11B1 P15538 2/20 0.33
▸ CYP11B2 P19099 2/20 0.33
▸ CETP P11597 1/20 0.33
▸ XDH P47989 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ SCN10A Q9Y5Y9 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ MMP14 P50281 1/20 0.32
▸ ADAM17 P78536 1/20 0.32
▸ MPO P05164 1/20 0.32
▸ GRIN1 Q05586 2/20 0.32
▸ GRIN2B Q13224 2/20 0.32
▸ S1PR1 P21453 1/20 0.31
▸ ALOX5AP P20292 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459646 0.93 MRGPRX4 (0.34) MAOBMRGPRX4CETPXDHKCNH2
SCHEMBL2460423 0.90 NR4A2 (0.41) MAOBMRGPRX4
SCHEMBL2458043 0.90 IGF1R (0.37) MRGPRX4MPOGRIN1GRIN2BPDE4A
SCHEMBL2459633 0.89 MAOB (0.39) MAOBMRGPRX4
SCHEMBL2458187 0.89 MAOB (0.39) MAOBMRGPRX4MPO
SCHEMBL2460200 0.89 MAOB (0.37) MAOBMRGPRX4
SCHEMBL2456898 0.88 NOS1 (0.35) MAOBMRGPRX4
SCHEMBL2461743 0.87 NR4A2 (0.39) MAOB
SCHEMBL2460724 0.87 MRGPRX4 (0.34) MRGPRX4
SCHEMBL2463293 0.87 MAOB (0.42) MAOBMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885CYP19A1 287/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885CYP19A1 287/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885CYP19A1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.